Prognostic impact of snoRNA signatures in non-ALCL PTCL subtypes. (A) HBII-239, U90, and U59b relative expression in AITL-overexpressing patients (group 1) and other patients (group 2) compared with the median expression in all AITL patients. (B) OS and PFS Kaplan-Meier analysis of group 2. (C) Relative expression of HBII-438A, U80, and HBII-239 in PTCL-NOS–overexpressing patients (group 1) and other patients (group 2) compared with the median expression in all PTCL-NOS samples. (D) OS and PFS Kaplan-Meier analysis of group 2. (E) HBII-239 relative expression in all non-ALCL PTCL patients compared with the median expression. (F) OS and PFS Kaplan-Meier analysis in HBII-239–overexpressing patients (group 1) and other patients (group 2). (G) HBII-239 and HBII-239–processed miRNA (has-miRNA-768-3p) relative expression in 37 randomly selected non-ALCL PTCL patients. *P < .05; **P < .01; ***P < .001.